BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease
Search BioPortfolio:       
BioNews
Biotechnology, Pharmaceutical, Life Science & Medical News
Track this topic with BioWatch News Alerts: Register | Login
search help

Search Results

Documents 1-25 out of 27 found
  Current Search:  daytrana: 27     

HTML
100%
Half Yearly Report
Press Release Basingstoke, UK and Philadelphia, US - August 7, 2008 - In order to meet its obligations under the Disclosure Rules and Transparency Rules of the United Kingdom Financial Services Authority, Shire Limited ('Shire') (LSE: SHP,...
London Stock Exchange:  Aug 7 2008 12:37PM
Matching: daytrana
Find similar documents
HTML
100%
Noven Announces 2008 Second Quarter Financial Results
- Noven Pharmaceuticals, Inc.

(NASDAQ:NOVN) today announced financial results for the second quarter and first half of 2008.

Noven reported net income of $4.5 million or $0.18 diluted earnings per share for the quarter ended June 30,...

DiGiTAL50:  Aug 7 2008 12:52PM
Matching: daytrana
Find similar documents
HTML
100%
Noven to receive $25 million payment from Shire
Payment of the milestone announced was triggered upon Shire's net sales of Daytrana exceeding $75 million in the 12-months preceding June 30, 2008.

Under Noven's agreement with Shire, the $25 million milestone is due to be paid in...

Pharmaceutical Business Review:  Aug 6 2008 3:33AM
Matching: daytrana
Find similar documents
HTML
100%
Noven Pharma Q2 Profit Declines Yet Tops Estimates; Revenues Up 31%
Noven Pharmaceuticals Inc.

(NOVN: News, Chart, Quote ) Wednesday reported a decline in second quarter profit hurt by higher expenses and a voluntary product recall charge, even as revenue increased 31% from the prior-year quarter.

RTTNews.com:  Aug 6 2008 2:46PM
Matching: daytrana
Find similar documents
HTML
100%
Noven Pharmaceuticals Inc to receive milestone from Shire Limited for Daytrana sales
(M2 EQUITYBITES via COMTEX) -- NOVN | Quote | Chart | News | PowerRating -- Noven Pharmaceuticals Inc (NASDAQ: NOVN), a specialty pharmaceutical company, reported on 4 August that it will receive the third and final USD25m milestone payment...
TradingMarkets:  Aug 5 2008 10:35AM
Matching: daytrana
Find similar documents
HTML
100%
Noven Pharmaceuticals Inc to receive milestone from Shire Limited for Daytrana sales
Noven Pharmaceuticals Inc (NASDAQ: NOVN), a specialty pharmaceutical company, reported on 4 August that it will receive the third and final USD25m milestone payment from Shire Limited on net sales of Daytrana (methylphenidate...
M2:  Aug 5 2008 9:53AM
Matching: daytrana
Find similar documents
HTML
100%
Noven Announces Triggering of $25 Million Daytrana Sales Milestone
MIAMI, Aug.

4, 2008--(BUSINESS WIRE)--Noven Pharmaceuticals, Inc.

(NASDAQ: NOVN) today announced that it has been advised by Shire Limited that Shires net sales of Daytrana (methylphenidate transdermal system) have triggered the...

Pharma Live:  Aug 4 2008 2:02PM
Matching: daytrana
Find similar documents
HTML
100%
Noven Announces Triggering of $25 Million Daytrana Sales Milestone
MIAMI, Aug.

4, 2008--(BUSINESS WIRE)--Noven Pharmaceuticals, Inc.

(NASDAQ: NOVN) today announced that it has been advised by Shire Limited that Shires net sales of Daytrana (methylphenidate transdermal system) have triggered the...

Therapeutics Daily:  Aug 4 2008 2:11PM
Matching: daytrana
Find similar documents
HTML
100%
Sales milestone met for Noven
Daytrana was launched in June 2006.

Payment of the milestone was triggered upon Shires net sales of Daytrana exceeding $75 million in the 12 months preceding June 30.

Under Novens agreement, the $25 million milestone is due...

East Bay Business Journal:  Aug 4 2008 9:03PM
Matching: daytrana
Find similar documents
HTML
100%
Noven Achieves $25M Milestone under Collaboration with Shire for ADHD Therapy
Noven Pharmaceuticals will receive $25 million from Shire under its agreement related to Daytrana.

Shire achieved a sales level previously agreed to by both firms, thus triggering this milestone fee.

Under the terms of the...

Genetic Engineering News:  Aug 4 2008 4:32PM
Matching: daytrana
Find similar documents
HTML
100%
Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgra
BASINGSTOKE, England and PHILADELPHIA, July 31 /PRNewswire-FirstCall/ -- Shire Limited the global specialty biopharmaceutical company announces results for the three months to June 30, 2008.

Q2 2008 Financial Highlights - Product sales up...

KRON4:  Jul 31 2008 3:37PM
Matching: daytrana
Find similar documents
HTML
100%
Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgra
BASINGSTOKE, England and PHILADELPHIA, July 31 /PRNewswire-FirstCall/ -- Shire Limited the global specialty biopharmaceutical company announces results for the three months to June 30, 2008.

Q2 2008 Financial Highlights - Product sales up...

KOTA Territory News:  Jul 31 2008 1:31PM
Matching: daytrana
Find similar documents
HTML
100%
Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgra
BASINGSTOKE, England and PHILADELPHIA, July 31 /PRNewswire-FirstCall/ -- Shire Limited (LSE: SHP, NASDAQ: SHPGY) the global specialty biopharmaceutical company announces results for the three months to June 30, 2008.

Q2 2008 Financial...

San Antonio Business Journal:  Jul 31 2008 12:48PM
Matching: daytrana
Find similar documents
HTML
100%
Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgra
ASINGSOE, England and PILADELPHIA, uly 31, 2008 /PRNewswire-FirstCall/ -- Shire Limited the global specialty biopharmaceutical company announces results for the three months to e 30, 2008.

Q2 2008 Financial Highlights - Product sales up 40...

Drugs.com:  Jul 31 2008 3:57PM
Matching: daytrana
Find similar documents
HTML
100%
Noven Pharmaceuticals Inc: Corporate and Strategic Assessment Report - Company Strategy, SWOT Analysis and 5-y
Published By: Datamonitor Page Count: 58 Order Code: R313-34249 Description Introduction Noven Pharmaceuticals (Noven) is a specialty pharmaceutical company engaged in the discovery, development, manufacture and commercialization of...
Mindbranch:  Jul 15 2008 2:54PM
Matching: daytrana
Find similar documents
HTML
100%
Shares of Miami-based drug firm tumble
Shares of Miami-based Noven Pharmaceuticals fell Monday after a Jefferies analyst cut his rating on the company, pointing to slower sales of key products and a weak pipeline.

The stock lost 98 cents, or 9.1 percent, to $9.80 in afternoon...

Miami Herald:  Jul 7 2008 8:24PM
Matching: daytrana
Find similar documents
HTML
100%
Analyst Actions: Jefferies Cuts Rating on Noven Pharma - Plunges 10%
(MidnightTrader via COMTEX News Network) -- Jefferies cut Noven Pharmaceuticals (NOVN) to 'underperform' vs 'hold' due to declining growth in sales of the Vivelle-Dot estrogen patch.

Sales of the Daytrana attention deficit...

Macro World Investor:  Jul 7 2008 8:20PM
Matching: daytrana
Find similar documents
HTML
100%
Noven Pharma falls after analyst cuts rating
NEW YORK (AP) - Shares of Noven Pharmaceuticals Inc.

fell Monday after a Jefferies analyst cut his rating on the company, pointing to slower sales of key products and a weak pipeline.

Analyst David Windley lowered his rating to ...

MSN Money:  Jul 7 2008 7:02PM
Matching: daytrana
Find similar documents
HTML
100%
Noven Pharma falls after analyst cuts rating
NEW YORK Shares of Noven Pharmaceuticals Inc.

fell Monday after a Jefferies analyst cut his rating on the company, pointing to slower sales of key products and a weak pipeline.

Analyst David Windley lowered his rating to 'Underperform'...

Business Week:  Jul 7 2008 6:44PM
Matching: daytrana
Find similar documents
HTML
100%
Noven Pharma falls after analyst cuts rating
NEW YORK - Shares of Noven Pharmaceuticals Inc.

fell Monday after a Jefferies analyst cut his rating on the company, pointing to slower sales of key products and a weak pipeline.

Analyst David Windley lowered his rating to 'Underperform'...

CNBC:  Jul 7 2008 5:38PM
Matching: daytrana
Find similar documents
HTML
100%
Noven Pharma falls after analyst cuts rating
Shares of Noven Pharmaceuticals Inc.

fell Monday after a Jefferies analyst cut his rating on the company, pointing to slower sales of key products and a weak pipeline.

Analyst David Windley lowered his rating to 'Underperform' from 'Hold...

Forbes.com:  Jul 7 2008 5:30PM
Matching: daytrana
Find similar documents
HTML
100%
Noven Pharma falls after analyst cuts rating
Analyst David Windley lowered his rating to 'Underperform' from 'Hold' due to declining growth in sales of the Vivelle-Dot estrogen patch and the Daytrana attention deficit hyperactivity disorder patch, which has been damaged by a...
Yahoo! Canada:  Jul 7 2008 5:26PM
Matching: daytrana
Find similar documents
HTML
100%
Noven Pharma falls after analyst cuts rating
NEW YORK (AP) -- Shares of Noven Pharmaceuticals Inc.

fell Monday after a Jefferies analyst cut his rating on the company, pointing to slower sales of key products and a weak pipeline.Analyst David Windley lowered his rating to ...

AP via Yahoo!:  Jul 7 2008 5:12PM
Matching: daytrana
Find similar documents
HTML
100%
Analyst Actions: Jefferies Cuts Rating on Noven Pharma - Plunges 10%
Jefferies also cut its price target to $9 per share from $11.

The stock last traded at $9 on April 30.

The company makes patches that deliver drugs through the skin and Jefferies believes there is little potential in Noven's pipeline.

Calibre Macro World:  Jul 7 2008 7:55PM
Matching: daytrana
Find similar documents
HTML
100%
Johnson & Johnson Grows Up a Little
Johnson & Johnson's (NYSE: JNJ) attention deficit hyperactivity disorder (ADHD) pill, Concerta, is growing up.

On Friday, the Food and Drug Administration approved the drug for adults.

Concerta, a long-acting version of Novartis'...

Motley Fool:  Jun 30 2008 9:03PM
Matching: daytrana
Find similar documents

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.  See User Agreement

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright © 1997-2008 - BioPortfolio Limited.